SCHEMBL6865780

SCHEMBL6865780

CC1CC(Nc2ccnc3cc(Cl)ccc23)C(C)CC1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT5B Q4FZB7 1/20 0.56
KMT5C Q86Y97 1/20 0.56
NSD2 O96028 1/20 0.53
KMT2A Q03164 3/20 0.51
ALDH1A1 P00352 3/20 0.51
KDM4E B2RXH2 2/20 0.51
MEN1 O00255 2/20 0.51
NR4A2 P43354 1/20 0.49
CYP1A2 P05177 1/20 0.49
FERMT2 Q96AC1 3/20 0.48
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
MAPT P10636 4/20 0.47
TDP1 Q9NUW8 3/20 0.47
CCR1 P32246 1/20 0.47
GAA P10253 1/20 0.46
LMNA P02545 1/20 0.46
PLA2G1B P04054 1/20 0.46
POLB P06746 1/20 0.46
XBP1 P17861 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6867495 1.00 KMT5B (0.56) KMT5BKMT5CNSD2KMT2AALDH1A1
SCHEMBL6861429 0.94 KMT5B (0.63) KMT5BKMT5CNSD2KMT2AALDH1A1
SCHEMBL6868439 0.85 KMT5B (0.53) KMT5BKMT5CNSD2KMT2AALDH1A1
SCHEMBL30817065 0.80 KMT5B (0.70) KMT5BKMT5CNSD2KMT2AALDH1A1
SCHEMBL30817045 0.80 KMT5B (0.70) KMT5BKMT5CNSD2KMT2AALDH1A1
SCHEMBL30817039 0.80 KMT5B (0.70) KMT5BKMT5CNSD2KMT2AALDH1A1
SCHEMBL7837345 0.80 KMT5B (0.70) KMT5BKMT5CNSD2KMT2AALDH1A1
SCHEMBL7826415 0.80 KMT5B (0.70) KMT5BKMT5CNSD2KMT2AALDH1A1
SCHEMBL9267916 0.79 KMT5B (0.76) KMT5BKMT5CNSD2KMT2AALDH1A1
SCHEMBL9271568 0.79 KMT5B (0.81) KMT5BKMT5CNSD2KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818772-B2 DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS ABBOTT LABORATORIES 2004-11-16 US disclosed
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor ABBVIE INC. 2003-12-11 US disclosed
WO-2003070244-A1 ANTAGONIST OF MELANIN CONCENTRATING HORMONE AND THEIR USES ABBOTT LABORATORIES (US) 2003-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor MCHR1, MCHR2, MC1R KMT5B 1214/4885KMT5C 1285/4885NSD2 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.